Last $9.70 USD
Change Today 0.00 / 0.00%
Volume 0.0
RBXZF On Other Exchanges
Natl India
As of 8:10 PM 12/11/14 All times are local (Market data is delayed by at least 15 minutes).

ranbaxy labora-unsp gdr regs (RBXZF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/11/14 - $10.80
52 Week Low
02/11/14 - $5.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ranbaxy labora-unsp gdr regs (RBXZF) Related Businessweek News

View More BusinessWeek News

ranbaxy labora-unsp gdr regs (RBXZF) Details

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbaxy Laboratories Limited operates in India, Europe, North America, the Asia Pacific, and Africa. The company was founded in 1961 and is headquartered in New Delhi, India. Ranbaxy Laboratories Limited is a subsidiary of Daiichi Sankyo Company, Ltd.

15,300 Employees
Last Reported Date: 07/1/14
Founded in 1961

ranbaxy labora-unsp gdr regs (RBXZF) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: 122.7M
Compensation as of Fiscal Year 2014.

ranbaxy labora-unsp gdr regs (RBXZF) Key Developments

Ranbaxy Laboratories Announces Delisting Of GDS From London Stock Exchange

Ranbaxy Laboratories Ltd. announced that trading on the London Stock Exchange "Admission to Trading Only" for Global Depositary Shares (GDS) (each representing 1 Ordinary Share of INR 5), fully paid has been cancelled from December 16, 2014 7:00am.

Ranbaxy Laboratories Announces Launch of Infimab

Ranbaxy Laboratories announced the launch of Infimab, the first Remicade (Infliximab) biosimilar in India. The drug is used in treatment of inflammatory diseases, including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and also psoriasis.

Ranbaxy Laboratories Announces Delisting Of GDS From Luxembourg Stock Exchange

With reference to the earlier letter dated October 16, 2014 regarding Termination of the Company's Global Depository Receipts Programme, in this regard, Ranbaxy Laboratories Ltd has now informed Bombay Stock Exchange that the Company have received a letter on October 31, 2014 from the Luxembourg Stock Exchange (LSE) (where GDS of the Company are listed) intimating that in view of the termination of the Deposit Agreement on December 15, 2014, they will de-list the GDS from the official list of the LSE and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBXZF:US $9.70 USD 0.00

RBXZF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,091 INR -0.70
Cadila Healthcare Ltd 1,582 INR -5.45
Richter Gedeon Nyrt 3,451 +21.00
Glenmark Pharmaceuticals Ltd 779.00 INR +1.85
Krka dd Novo mesto €58.50 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation RBXZF Industry Range
Price/Earnings 100.0x
Price/Sales 2.3x
Price/Book 7.0x
Price/Cash Flow 63.1x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RANBAXY LABORA-UNSP GDR REGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at